Scioderm, Inc. was acquired by Amicus Therapeutics, Inc. in September of 2015. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare genetic diseases. Amicus, together with Scioderm, was developing an investigational topical treatment (SD-101) for people with Epidermolysis Bullosa (EB), which is a rare genetic connective tissue disorder. In September of 2017, results of a Phase 3 clinical study to assess the efficacy and safety of SD-101, showed that it did not show a statistically significant difference from placebo. Subsequently, Amicus discontinued the program, but shared the clinical data and additional information related to the EB program with key stakeholders including other companies with investigational treatments for EB as well as the broader EB community.